JP2013519367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519367A5 JP2013519367A5 JP2012552459A JP2012552459A JP2013519367A5 JP 2013519367 A5 JP2013519367 A5 JP 2013519367A5 JP 2012552459 A JP2012552459 A JP 2012552459A JP 2012552459 A JP2012552459 A JP 2012552459A JP 2013519367 A5 JP2013519367 A5 JP 2013519367A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sequence
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 105
- 102000012000 CXCR4 Receptors Human genes 0.000 claims 52
- 108010061299 CXCR4 Receptors Proteins 0.000 claims 52
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 24
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 150000001413 amino acids Chemical class 0.000 claims 13
- 238000006467 substitution reaction Methods 0.000 claims 11
- 241001465754 Metazoa Species 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 9
- 238000011282 treatment Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000005764 inhibitory process Effects 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 230000014509 gene expression Effects 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 229940127121 immunoconjugate Drugs 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000009545 invasion Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 229940039227 diagnostic agent Drugs 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 229940121819 ATPase inhibitor Drugs 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100032530 Glypican-3 Human genes 0.000 claims 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 208000003874 Simpson-Golabi-Behmel syndrome Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910001424 calcium ion Inorganic materials 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000010807 negative regulation of binding Effects 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- -1 other antibody Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30306010P | 2010-02-10 | 2010-02-10 | |
| GB1002238.2 | 2010-02-10 | ||
| GBGB1002238.2A GB201002238D0 (en) | 2010-02-10 | 2010-02-10 | Antibodies |
| US61/303,060 | 2010-02-10 | ||
| PCT/GB2011/000175 WO2011098762A2 (en) | 2010-02-10 | 2011-02-10 | Antibodies against cxcr4 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016149925A Division JP2017012179A (ja) | 2010-02-10 | 2016-07-29 | 抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013519367A JP2013519367A (ja) | 2013-05-30 |
| JP2013519367A5 true JP2013519367A5 (enExample) | 2014-03-27 |
| JP6045914B2 JP6045914B2 (ja) | 2016-12-14 |
Family
ID=42110504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552459A Expired - Fee Related JP6045914B2 (ja) | 2010-02-10 | 2011-02-10 | 抗体 |
| JP2016149925A Withdrawn JP2017012179A (ja) | 2010-02-10 | 2016-07-29 | 抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016149925A Withdrawn JP2017012179A (ja) | 2010-02-10 | 2016-07-29 | 抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8748107B2 (enExample) |
| EP (1) | EP2534177A2 (enExample) |
| JP (2) | JP6045914B2 (enExample) |
| KR (1) | KR20120130767A (enExample) |
| CN (1) | CN103003306B (enExample) |
| AU (1) | AU2011214179B2 (enExample) |
| BR (1) | BR112012020173A2 (enExample) |
| CA (1) | CA2788400A1 (enExample) |
| CO (1) | CO6630117A2 (enExample) |
| EA (1) | EA201290759A1 (enExample) |
| GB (1) | GB201002238D0 (enExample) |
| MX (1) | MX2012009144A (enExample) |
| NZ (1) | NZ601943A (enExample) |
| SG (1) | SG182795A1 (enExample) |
| WO (1) | WO2011098762A2 (enExample) |
| ZA (1) | ZA201206055B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP3626739A1 (en) | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| EP2977386A1 (en) * | 2012-08-31 | 2016-01-27 | Argen-X Nv | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
| KR20160132031A (ko) * | 2014-02-19 | 2016-11-16 | 마이크로콘스탄스 차이나 아이엔씨 | 케모카인 수용체 대항물질 및 그것의 병용 요법 |
| JP2018505144A (ja) * | 2014-12-17 | 2018-02-22 | キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ | 抗ｃｘｃｌ１２抗体分子およびその使用 |
| UA125433C2 (uk) * | 2015-07-23 | 2022-03-09 | Бьорінґер Інґельхайм Інтернаціональ Ґмбх | Націлена на іl-23а і фактор активації в-лімфоцитів (baff) сполука та її застосування |
| WO2017132202A1 (en) | 2016-01-25 | 2017-08-03 | Nant Holdings Ip, Llc | Nk cells with altered cxcl12/cxcr4 signaling |
| US10111235B2 (en) * | 2016-02-15 | 2018-10-23 | Spidercloud Wireless, Inc. | Methods for centralized channel selection across different cells in a radio access network |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| KR20210031898A (ko) | 2018-07-13 | 2021-03-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 전염병을 치료하기 위한 공동수용체 시스템 |
| EP4087657A1 (en) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| US20240360204A1 (en) * | 2021-05-27 | 2024-10-31 | The United States Government As Represented By The Department Of Veterans Affairs | Human Monoclonal Antibodies Specific to Streptolysin O and Methods of Use |
| EP4635310A1 (en) | 2022-12-12 | 2025-10-22 | Japan Tobacco Inc. | Tobacco sheet, method for producing tobacco sheet, tobacco filler, and smoking article |
| CN117003876B (zh) * | 2023-08-31 | 2024-06-18 | 恺佧生物科技(上海)有限公司 | 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| DE19801265C1 (de) | 1998-01-15 | 1999-08-12 | Deutsches Krebsforsch | Inhibierung von CD95-unabhängiger Apoptose bei AIDS |
| US6863887B1 (en) | 1998-03-30 | 2005-03-08 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
| US6610834B1 (en) | 1998-11-18 | 2003-08-26 | Peter I. Lobo | Human IgM antibodies to chemokine receptors |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| IL145941A (en) | 1999-04-28 | 2007-08-19 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US7005503B2 (en) | 2002-02-08 | 2006-02-28 | Genetastix Corporation | Human monoclonal antibody against coreceptors for human immunodeficiency virus |
| AU2003209059A1 (en) | 2002-02-08 | 2003-09-02 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
| DE10240064A1 (de) * | 2002-08-30 | 2004-03-11 | Universitätsklinikum Freiburg | CXCR4-Rezeptor-Antagonisten |
| US20050266009A1 (en) | 2003-06-30 | 2005-12-01 | Savient Pharmaceuticals, Inc. | Antibodies and uses thereof |
| WO2006124013A2 (en) * | 2004-04-30 | 2006-11-23 | Five Prime Therapeutics, Inc. | Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use |
| CA2597717C (en) | 2005-02-18 | 2014-10-21 | Dana-Farber Cancer Institute | Antibodies against cxcr4 and methods of use thereof |
| ES2625798T3 (es) * | 2006-10-02 | 2017-07-20 | E. R. Squibb & Sons, L.L.C. | Anticuerpos humanos que se unen a CXCR4 y usos de los mismos |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| EA201071300A1 (ru) | 2008-05-14 | 2011-06-30 | Эли Лилли Энд Компани | Антитела к cxcr4 |
-
2010
- 2010-02-10 GB GBGB1002238.2A patent/GB201002238D0/en not_active Ceased
-
2011
- 2011-02-10 CA CA2788400A patent/CA2788400A1/en not_active Abandoned
- 2011-02-10 JP JP2012552459A patent/JP6045914B2/ja not_active Expired - Fee Related
- 2011-02-10 US US13/024,698 patent/US8748107B2/en not_active Expired - Fee Related
- 2011-02-10 WO PCT/GB2011/000175 patent/WO2011098762A2/en not_active Ceased
- 2011-02-10 SG SG2012056321A patent/SG182795A1/en unknown
- 2011-02-10 KR KR1020127023204A patent/KR20120130767A/ko not_active Ceased
- 2011-02-10 MX MX2012009144A patent/MX2012009144A/es not_active Application Discontinuation
- 2011-02-10 AU AU2011214179A patent/AU2011214179B2/en not_active Ceased
- 2011-02-10 EP EP11730035A patent/EP2534177A2/en not_active Withdrawn
- 2011-02-10 EA EA201290759A patent/EA201290759A1/ru unknown
- 2011-02-10 CN CN201180019263.1A patent/CN103003306B/zh not_active Expired - Fee Related
- 2011-02-10 NZ NZ601943A patent/NZ601943A/en not_active IP Right Cessation
- 2011-02-10 BR BR112012020173A patent/BR112012020173A2/pt not_active IP Right Cessation
-
2012
- 2012-08-13 ZA ZA2012/06055A patent/ZA201206055B/en unknown
- 2012-09-03 CO CO12150358A patent/CO6630117A2/es unknown
-
2014
- 2014-05-16 US US14/279,728 patent/US9353185B2/en not_active Expired - Fee Related
-
2016
- 2016-05-11 US US15/152,414 patent/US20160244527A1/en not_active Abandoned
- 2016-07-29 JP JP2016149925A patent/JP2017012179A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7320498B2 (ja) | Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法 | |
| CN111454357B (zh) | 一种含有抗体的肿瘤治疗剂的开发和应用 | |
| CA3090008A1 (en) | Anti-cd73 antibodies and uses thereof | |
| AU2020294364A1 (en) | Anti-Galectin-9 antibodies and uses thereof | |
| AU2018312222A1 (en) | Anti-CD47 antibodies and uses thereof | |
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| WO2018137576A1 (zh) | 抗pd-1单克隆抗体及其制备方法和应用 | |
| CN116239698A (zh) | 双功能融合蛋白及其医药用途 | |
| JP2013502913A5 (enExample) | ||
| JP2012529281A5 (enExample) | ||
| JP2012529280A5 (enExample) | ||
| US9631024B2 (en) | Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors | |
| US20210032331A1 (en) | Anti-lag 3 antibodies and uses thereof | |
| AU2016369307A1 (en) | Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F | |
| JP2020520912A (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| JP7392145B2 (ja) | 免疫療法のためのｔ細胞二重特異性抗体の作製における最適化された抗ｃｄ３アーム | |
| TW202221035A (zh) | 抗ilt2抗體及其用途 | |
| US20240209093A1 (en) | Single domain pd-l1 antibodies | |
| WO2023098785A1 (zh) | 抗4-1bb抗体及其用途 | |
| JP7557457B2 (ja) | 抗ヒトｐｄ－ｌ１抗体とその使用 | |
| CN111683680B (zh) | 抗rspo3抗体 | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| TW202400662A (zh) | 結合ｐｄ－ｌ１和ｃｌｄｎ１８．２的抗體及其用途 | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 |